The United States is signaling it may open a formal trade investigation into Switzerland’s pharmaceutical industry, a move that could reshape one of the most consequential economic relationships in global healthcare.

For context, pharmaceuticals make up nearly half of all Swiss exports to the US, totaling roughly $35.5 billion in 2024. That’s not a minor trade lane. That’s the backbone of Switzerland’s economic ties with its largest trading partner.

The tariff saga so far

US tariffs on Swiss goods peaked at 39% in August 2025, imposed under Section 232, the same national security provision that previously targeted steel and aluminum imports from various countries.

Pharmaceuticals were initially carved out of the broader tariff action. But the threat of inclusion under Section 232 probes loomed large enough to send Swiss industry executives scrambling for contingency plans.

A US-Swiss trade deal struck in November 2025 capped tariffs on pharmaceuticals at 15%. In exchange, Swiss firms made commitments that, by any measure, were enormous.

Roche pledged $50 billion in US investments. Novartis committed $23 billion. Combined with other Swiss industry pledges, the total package came to roughly $200 billion directed toward bolstering manufacturing and operations on American soil.

Why this matters now

The potential probe would examine whether Swiss pharmaceutical imports pose national security concerns, a framing that gives the executive branch broad authority to impose restrictions.

On June 18, 2026, the US initiated a Section 301 investigation into Germany’s drug pricing policies. Section 301 is a different tool from Section 232, but the pattern is clear: Washington is systematically scrutinizing how European governments and industries operate in the pharmaceutical space.

Novartis has already taken defensive measures. The company established stockpiles within the US sufficient to sustain operations through mid-2026, with plans for local manufacturing capacity coming online within three to four years. Roche is pursuing a similar strategy of building domestic production capabilities.

What this means for investors

Roche and Novartis are now fundamentally altering their manufacturing strategies to accommodate US trade policy. That capital reallocation — $73 billion between just the two firms — involves construction costs, supply chain restructuring, regulatory compliance in new jurisdictions, and workforce development, all of which compress margins in the near term.

For investors in these companies, the key question is whether the 15% tariff cap holds. If a new Section 232 investigation concludes that Swiss pharma imports pose a national security risk, tariffs could climb back toward 39% or beyond.

If the US is willing to investigate both German pricing policies and Swiss import dependencies in the same six-month window, no major European pharmaceutical exporter is safe from scrutiny. Companies like AstraZeneca, Sanofi, and GSK should be watching closely.